Table S1 from Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in <i>EGFR</i>-Mutant Non–Small Cell Lung Cancer Cells

crossref(2023)

引用 0|浏览7
暂无评分
摘要

Table S1. ClearSeq Cancer Panel Gene List

更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要